Prediction and significance of cancer in idiopathic inflammatory myositis
Active Project Grant Awarded Last action
- Award ID
- R01AR083912
- Recipient
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,611,028
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 45% complete
- Place of performance
- Baltimore, MD 21205, USA
Award details come from USAspending.gov.
Description
- Abstract
- Idiopathic inflammatory myopathies (IIM) comprise a heterogeneous group of chronic autoimmune diseases that can lead to severe muscle weakness and chronic disability; however, IT is their association with contemporaneous cancer (cancer-associated myositis, cam), that is responsible for mortality rates approaching 50%. Myositis-specific autoantibodies have emerged as important biomarkers, and are associated with an increased risk of cancer, but are of limited utility in predicting if cancer will emerge in an individual patient - the majority of patients with the highest-risk antibodies for cam never have cancer diagnosed. Despite multiple studies focused on the myositis-cancer association, the ability to predict cancer, and the biologic relationship between cancer and myositis, remain poorly understood. Given the inability to predict cancer, the current standard is that the majority of patients with IIM are aggressively screened for cancer for multiple years following diagnosis, leading to increased cost, radiation, and false positive results. Beyond cam prediction, the biologic relationship between IIM and cancer has been historically neglected; specifically, how cancer emergence and elimination impact IIM outcomes is largely unknown. However, insights gained from the careful study of cancer emergence/elimination in IIM can inform research into disease mechanism, particularly given that cancer has been hypothesized to be responsible for IIM development - so called "cancer-induced autoimmunity". In this setting, the recent development of highly sensitive, novel cancer detection technologies have enabled the robust study of cancer in IIM cohorts. The overall goals of this proposal are to (I) optimize the prediction of cam at the individual patient level and (II) determine how the emergence and elimination of cancer influence IIM clinical outcomes. In aim 1, we will utilize three of the largest cohorts of IIM patients in the united states to develop and validate a cancer prediction model to inform clinical decision-making. In aim 2, the relationship between cancer emergence, cancer elimination, and IIM outcomes will be determined using novel liquid biopsy cancer detection technologies, providing insights into IIM pathogenesis and improvements in disease monitoring. Understanding the cancer-IIM relationship will ultimately enable development of novel, effective treatment strategies that are focused on cancer detection/elimination rather than the currently used non-specific immunosuppression approaches.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $523,421 | |
| Amendment | $512,586 | |
| Original award | $575,021 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $190,096 | |
| The Leland Stanford Junior University | $217,326 |
Quick answers
Who received award R01AR083912?
R01AR083912 was awarded to The Johns Hopkins University by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on August 21, 2024.
How much is award R01AR083912 worth?
$1,611,028 has been obligated on R01AR083912.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award